Demant A/S
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Hol… Read more
Demant A/S (WILLF) - Net Assets
Latest net assets as of December 2025: $9.90 Billion USD
Based on the latest financial reports, Demant A/S (WILLF) has net assets worth $9.90 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.99 Billion) and total liabilities ($29.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.90 Billion |
| % of Total Assets | 25.39% |
| Annual Growth Rate | 14.63% |
| 5-Year Change | 24.0% |
| 10-Year Change | 42.07% |
| Growth Volatility | 33.78 |
Demant A/S - Net Assets Trend (2002–2025)
This chart illustrates how Demant A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Demant A/S (2002–2025)
The table below shows the annual net assets of Demant A/S from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.90 Billion | +2.62% |
| 2024-12-31 | $9.64 Billion | +3.28% |
| 2023-12-31 | $9.34 Billion | +9.06% |
| 2022-12-31 | $8.56 Billion | +7.28% |
| 2021-12-31 | $7.98 Billion | -3.60% |
| 2020-12-31 | $8.28 Billion | +8.29% |
| 2019-12-31 | $7.64 Billion | +8.30% |
| 2018-12-31 | $7.06 Billion | -5.03% |
| 2017-12-31 | $7.43 Billion | +6.70% |
| 2016-12-31 | $6.97 Billion | +7.17% |
| 2015-12-31 | $6.50 Billion | +16.40% |
| 2014-12-31 | $5.58 Billion | +9.92% |
| 2013-12-31 | $5.08 Billion | +25.15% |
| 2012-12-31 | $4.06 Billion | +22.85% |
| 2011-12-31 | $3.30 Billion | +35.23% |
| 2010-12-31 | $2.44 Billion | +87.64% |
| 2009-12-31 | $1.30 Billion | +140.91% |
| 2008-12-31 | $540.50 Million | +24.31% |
| 2007-12-31 | $434.79 Million | -35.18% |
| 2006-12-31 | $670.80 Million | -11.32% |
| 2005-12-31 | $756.47 Million | +17.18% |
| 2004-12-31 | $645.57 Million | +23.63% |
| 2003-12-31 | $522.16 Million | +22.07% |
| 2002-12-31 | $427.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Demant A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2846.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.40 Billion | 105.92% |
| Common Stock | $42.90 Million | 0.44% |
| Other Comprehensive Income | $-624.58 Million | -6.36% |
| Total Equity | $9.82 Billion | 100.00% |
Demant A/S Competitors by Market Cap
The table below lists competitors of Demant A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oil India Limited
NSE:OIL
|
$2.95 Billion |
|
INDIVIOR PLC DL 050
F:2IVB
|
$2.96 Billion |
|
Corcept Therapeutics Incorporated
NASDAQ:CORT
|
$2.96 Billion |
|
Gruma SAB de CV
OTCGREY:GPAGF
|
$2.96 Billion |
|
PotlatchDeltic Corp
NASDAQ:PCH
|
$2.95 Billion |
|
Brembo S.p.A.
OTCGREY:BRBOF
|
$2.95 Billion |
|
HOCHTIEF Aktiengesellschaft
PINK:HOCFF
|
$2.95 Billion |
|
JCHX Mining Management Co Ltd
SHG:603979
|
$2.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Demant A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,564,000,000 to 9,819,707,000, a change of 255,707,000 (2.7%).
- Net income of 1,541,500,490 contributed positively to equity growth.
- Share repurchases of 580,681,737 reduced equity.
- Other comprehensive income decreased equity by 734,582,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.54 Billion | +15.7% |
| Share Repurchases | $580.68 Million | -5.91% |
| Other Comprehensive Income | $-734.58 Million | -7.48% |
| Other Changes | $29.47 Million | +0.3% |
| Total Change | $- | 2.67% |
Book Value vs Market Value Analysis
This analysis compares Demant A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.70x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 27.92x to 0.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $1.17 | $32.58 | x |
| 2003-12-31 | $1.49 | $32.58 | x |
| 2004-12-31 | $1.93 | $32.58 | x |
| 2005-12-31 | $2.33 | $32.58 | x |
| 2006-12-31 | $2.14 | $32.58 | x |
| 2007-12-31 | $1.41 | $32.58 | x |
| 2008-12-31 | $1.84 | $32.58 | x |
| 2009-12-31 | $4.47 | $32.58 | x |
| 2010-12-31 | $8.37 | $32.58 | x |
| 2011-12-31 | $11.34 | $32.58 | x |
| 2012-12-31 | $14.25 | $32.58 | x |
| 2013-12-31 | $17.95 | $32.58 | x |
| 2014-12-31 | $20.08 | $32.58 | x |
| 2015-12-31 | $24.06 | $32.58 | x |
| 2016-12-31 | $26.39 | $32.58 | x |
| 2017-12-31 | $28.95 | $32.58 | x |
| 2018-12-31 | $28.30 | $32.58 | x |
| 2019-12-31 | $31.35 | $32.58 | x |
| 2020-12-31 | $34.41 | $32.58 | x |
| 2021-12-31 | $33.97 | $32.58 | x |
| 2022-12-31 | $37.88 | $32.58 | x |
| 2023-12-31 | $41.48 | $32.58 | x |
| 2024-12-31 | $44.03 | $32.58 | x |
| 2025-12-31 | $46.47 | $32.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Demant A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.70%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.69%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 3.97x
- Recent ROE (15.70%) is below the historical average (58.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 135.25% | 14.75% | 1.97x | 4.66x | $535.79 Million |
| 2003 | 118.41% | 15.98% | 1.92x | 3.86x | $566.06 Million |
| 2004 | 111.05% | 16.66% | 1.76x | 3.78x | $652.35 Million |
| 2005 | 104.51% | 17.48% | 1.56x | 3.82x | $714.94 Million |
| 2006 | 134.28% | 17.71% | 1.62x | 4.67x | $833.67 Million |
| 2007 | 209.92% | 16.30% | 1.47x | 8.74x | $851.89 Million |
| 2008 | 126.25% | 12.70% | 1.37x | 7.26x | $628.35 Million |
| 2009 | 61.05% | 13.94% | 1.23x | 3.55x | $664.69 Million |
| 2010 | 40.46% | 14.34% | 1.02x | 2.78x | $744.08 Million |
| 2011 | 36.30% | 14.90% | 1.05x | 2.32x | $868.00 Million |
| 2012 | 28.39% | 13.48% | 0.97x | 2.16x | $746.90 Million |
| 2013 | 25.29% | 13.95% | 0.89x | 2.04x | $776.90 Million |
| 2014 | 23.74% | 14.19% | 0.83x | 2.01x | $767.40 Million |
| 2015 | 22.10% | 13.46% | 0.74x | 2.21x | $786.10 Million |
| 2016 | 20.96% | 12.16% | 0.77x | 2.23x | $762.90 Million |
| 2017 | 23.62% | 13.30% | 0.81x | 2.18x | $1.01 Billion |
| 2018 | 25.86% | 13.08% | 0.78x | 2.54x | $1.12 Billion |
| 2019 | 19.15% | 9.78% | 0.69x | 2.85x | $698.40 Million |
| 2020 | 13.59% | 7.75% | 0.66x | 2.66x | $296.00 Million |
| 2021 | 31.50% | 14.04% | 0.72x | 3.12x | $1.72 Billion |
| 2022 | 24.32% | 10.57% | 0.66x | 3.49x | $1.23 Billion |
| 2023 | 19.39% | 8.00% | 0.73x | 3.30x | $869.40 Million |
| 2024 | 24.96% | 10.65% | 0.69x | 3.39x | $1.43 Billion |
| 2025 | 15.70% | 6.69% | 0.59x | 3.97x | $559.53 Million |
Industry Comparison
This section compares Demant A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Demant A/S (WILLF) | $9.90 Billion | 135.25% | 2.94x | $2.95 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |